Top

Published in:

01-12-2020 | Bullous Pemphigoid | Special Article

Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors

Authors: Jennifer Choi, Ronald Anderson, Ada Blidner, Tim Cooksley, Michael Dougan, Ilya Glezerman, Pamela Ginex, Monica Girotra, Dipti Gupta, Douglas Johnson, Vickie R. Shannon, Maria Suarez-Almazor, Bernardo L. Rapoport, Mario E. Lacouture

Published in: Supportive Care in Cancer | Issue 12/2020

Abstract

Immune checkpoint inhibitors (ICIs) frequently result in cutaneous immune-related adverse events (IrAEs). Although the majority of these events are mild-to-moderate in severity, up to 5% are severe, which may lead to morbidity and dose interruption or discontinuation of ICI therapy. In addition, up to 25% of dermatologic IrAEs are corticosteroid-refractory or corticosteroid-dependent. These 2020 MASCC recommendations cover the diagnosis and management of cutaneous IrAEs with a focus on moderate-to-severe and corticosteroid-resistant events. Although the usage of immune-suppressive therapy has been advocated in this setting, there is a lack of randomized clinical trial data to provide a compelling level of evidence of its therapeutic benefit.

Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, Izzeddine H, Marabelle A, Champiat S, Berdelou A, Lanoy E, Texier M, Libenciuc C, Eggermont AM, Soria JC, Mateus C, Robert C (2016) Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 13(8):473–486. https://doi.org/10.1038/nrclinonc.2016.58CrossRefPubMed

Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5(1):95. https://doi.org/10.1186/s40425-017-0300-zCrossRefPubMedPubMedCentral

Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB (2017) Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol 8:49. https://doi.org/10.3389/fphar.2017.00049CrossRefPubMedPubMedCentral

Hassel JC, Heinzerling L, Aberle J, Bähr O, Eigentler TK, Grimm MO, Grünwald V, Leipe J, Reinmuth N, Tietze JK, Trojan J, Zimmer L, Gutzmer R (2017) Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. Cancer Treat Rev 57:36–49. https://doi.org/10.1016/j.ctrv.2017.05.003CrossRefPubMed

Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K, ESMO Guidelines Committee (2017) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl_4):iv119–iv142. https://doi.org/10.1093/annonc/mdx225CrossRefPubMed

Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA, National Comprehensive Cancer Network (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36(17):1714–1768. https://doi.org/10.1200/JCO.2017.77.6385CrossRefPubMed

Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS (2016) Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22(4):886–894. https://doi.org/10.1158/1078-0432.CCR-15-1136CrossRefPubMed

Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, Lin K, Quaglino P, Rappersberger K, Ortiz-Urda S (2015) Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 151(11):1206–1212. https://doi.org/10.1001/jamadermatol.2015.1916CrossRefPubMedPubMedCentral

Hwang SJ, Carlos G, Wakade D, Byth K, Kong BY, Chou S, Carlino MS, Kefford R, Fernandez-Penas P (2016) Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol 74(3):455–461 e1. https://doi.org/10.1016/j.jaad.2015.10.029CrossRefPubMed

10.

Shi VJ, Rodic N, Gettinger S, Leventhal JS, Neckman JP, Girardi M, Bosenberg M, Choi JN (2016) Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol 152(10):1128–1136. https://doi.org/10.1001/jamadermatol.2016.2226CrossRefPubMedPubMedCentral

11.

Sibaud V (2018) Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol 19(3):345–361. https://doi.org/10.1007/s40257-017-0336-3CrossRefPubMed

12.

Collins LK, Chapman MS, Carter JB, Samie FH (2017) Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer 41(2):125–128. https://doi.org/10.1016/j.currproblcancer.2016.12.001CrossRefPubMed

13.

Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, Motzer RJ, Wu S, Busam KJ, Wolchok JD, Lacouture ME (2016) Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 60:12–25. https://doi.org/10.1016/j.ejca.2016.02.010CrossRefPubMedPubMedCentral

14.

Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP (2016) Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol 28(4):254–263. https://doi.org/10.1097/CCO.0000000000000290CrossRefPubMed

15.

Chou S, Hwang SJ, Carlos G, Wakade D, Fernandez-Penas P (2017) Histologic assessment of lichenoid dermatitis observed in patients with advanced malignancies on antiprogramed cell death-1 (anti-PD-1) therapy with or without ipilimumab. Am J Dermatopathol 39(1):23–27. https://doi.org/10.1097/DAD.0000000000000587CrossRefPubMed

16.

Schaberg KB, Novoa RA, Wakelee HA, Kim J, Cheung C, Srinivas S, Kwong BY (2016) Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. J Cutan Pathol 43(4):339–346. https://doi.org/10.1111/cup.12666CrossRefPubMed

17.

Joseph RW, Cappel M, Goedjen B, Gordon M, Kirsch B, Gilstrap C, Bagaria S, Jambusaria-Pahlajani A (2015) Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy. Cancer Immunol Res 3(1):18–22. https://doi.org/10.1158/2326-6066.CIR-14-0134CrossRefPubMed

18.

Chia PL, John T (2016) Severe psoriasis flare after anti-programmed death ligand 1 (PD-L1) therapy for metastatic non-small cell lung cancer (NSCLC). J Immunother 39(5):202–204. https://doi.org/10.1097/CJI.0000000000000121CrossRefPubMed

19.

Bonigen J, Raynaud-Donzel C, Hureaux J, Kramkimel N, Blom A, Jeudy G, Breton AL, Hubiche T, Bedane C, Legoupil D, Pham-Ledard A, Charles J, Pérol M, Gérard E, Combemale P, Bonnet D, Sigal ML, Mahé E, Groupe de Recherche sur le Psoriasis and the Groupe Cancérologie Cutanée of the Société Française de Dermatologie the GEM Resopso, Apsoderm and the Groupe Français de Pneumo-Cancérologie (2017) Anti-PD1-induced psoriasis: a study of 21 patients. J Eur Acad Dermatol Venereol 31(5):e254–e257. https://doi.org/10.1111/jdv.14011CrossRefPubMed

20.

Kwon CW, Land AS, Smoller BR, Scott G, Beck LA, Mercurio MG (2017) Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitor. J Eur Acad Dermatol Venereol 31(8):e349–e350. https://doi.org/10.1111/jdv.14143CrossRefPubMed

21.

Rofe O, Bar-Sela G, Keidar Z, Sezin T, Sadik CD, Bergman R (2017) Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression. Clin Exp Dermatol 42(3):309–312. https://doi.org/10.1111/ced.13042CrossRefPubMed

22.

Russo I, Sacco G, Frega S, Polo V, Pasello G, Alaibac M (2017) Immunotherapy-related skin toxicity: bullous pemphigoid in a lung adenocarcinoma patient treated with the anti-PDL1 antibody atezolizumab. Eur J Dermatol 27(2):205–208. https://doi.org/10.1684/ejd.2016.2959CrossRefPubMed

23.

Lopez AT, Geskin L (2018) A case of nivolumab-induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein-1/programmed death ligand-1 inhibitors and recommendations for diagnosis and management. Oncologist 23(10):1119–1126. https://doi.org/10.1634/theoncologist.2018-0128CrossRefPubMedPubMedCentral

24.

Lopez AT, Khanna T, Antonov N, Audrey-Bayan C, Geskin L (2018) A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors. Int J Dermatol 57(6):664–669. https://doi.org/10.1111/ijd.13984CrossRefPubMed

25.

Naidoo J, Schindler K, Querfeld C, Busam K, Cunningham J, Page DB, Postow MA, Weinstein A, Lucas AS, Ciccolini KT, Quigley EA, Lesokhin AM, Paik PK, Chaft JE, Segal NH, D'Angelo SP, Dickson MA, Wolchok JD, Lacouture ME (2016) Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res 4(5):383–389. https://doi.org/10.1158/2326-6066.CIR-15-0123CrossRefPubMedPubMedCentral

26.

Vivar KL, Deschaine M, Messina J, Divine JM, Rabionet A, Patel N, Harrington MA, Seminario-Vidal L (2017) Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol 44(4):381–384. https://doi.org/10.1111/cup.12876CrossRefPubMed

27.

Griffin LL, Cove-Smith L, Alachkar H, Radford JA, Brooke R, Linton KM (2018) Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma. JAAD Case Rep 4(3):229–231. https://doi.org/10.1016/j.jdcr.2017.09.028CrossRefPubMedPubMedCentral

28.

Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok JD (2015) Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26(12):2375–2391. https://doi.org/10.1093/annonc/mdv383CrossRefPubMedPubMedCentral

29.

Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, Hassel JC, Meier F, Tietze JK, Thomas I, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM (2016) Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 60:190–209. https://doi.org/10.1016/j.ejca.2016.02.025CrossRefPubMed

30.

Goldinger SM, Stieger P, Meier B, Micaletto S, Contassot E, French LE, Dummer R (2016) Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res 22(16):4023–4029. https://doi.org/10.1158/1078-0432.CCR-15-2872CrossRefPubMed

31.

Curry JL, Tetzlaff MT, Nagarajan P, Drucker C, Diab A, Hymes SR, Duvic M, Hwu WJ, Wargo JA, Torres-Cabala CA, Rapini RP, Prieto VG (2017) Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol 44(2):158–176. https://doi.org/10.1111/cup.12858CrossRefPubMed

32.

Saw S, Lee HY, Ng QS (2017) Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients. Eur J Cancer 81:237–239. https://doi.org/10.1016/j.ejca.2017.03.026CrossRefPubMed

33.

Ransohoff JD, Kwong BY (2017) Cutaneous adverse events of targeted therapies for hematolymphoid malignancies. Clin Lymphoma Myeloma Leuk 17(12):834–851. https://doi.org/10.1016/j.clml.2017.07.005CrossRefPubMed

34.

Ma VT, Katzman CS, Palmbos PL, Patel RM, Gudjonsson JE, Alva AS (2020) NB-UVB phototherapy in the treatment of anti-PD-1 inhibitor induced psoriasis: a case report. Curr Probl Cancer Case Rep. https://doi.org/10.1016/j.cpccr.2020.100004

35.

Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS (2019) Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. J Am Acad Dermatol 80(4):990–997. https://doi.org/10.1016/j.jaad.2018.10.062CrossRefPubMed

36.

Fattore D, Annunziata MC, Panariello L, Marasca C, Fabbrocini G (2019) Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast. Eur J Cancer 110:107–109. https://doi.org/10.1016/j.ejca.2019.01.010CrossRefPubMed

37.

Politi A, Angelos D, Mauri D, Zarkavelis G, Pentheroudakis G (2020) A case report of psoriasis flare following immunotherapy: report of an important entity and literature review. SAGE Open Med Case Rep 8:2050313X19897707. https://doi.org/10.1177/2050313X19897707CrossRefPubMedPubMedCentral

38.

Johnson D, Patel AB, Uemura MI, Trinh VA, Jackson N, Zobniw CM, Tetzlaff MT, Hwu P, Curry JL, Diab A (2019) IL17A blockade successfully treated psoriasiform dermatologic toxicity from immunotherapy. Cancer Immunol Res 7(6):860–865. https://doi.org/10.1158/2326-6066.CIR-18-0682CrossRefPubMed

39.

Singer S, Nelson CA, Lian CG, Dewan AK, LeBoeuf NR (2019) Nonbullous pemphigoid secondary to PD-1 inhibition. JAAD Case Rep 5(10):898–903. https://doi.org/10.1016/j.jdcr.2019.07.015CrossRefPubMedPubMedCentral

40.

Damsky W, Kole L, Tomayko MM (2016) Development of bullous pemphigoid during nivolumab therapy. JAAD Case Rep 2(6):442–444. https://doi.org/10.1016/j.jdcr.2016.05.009CrossRefPubMedPubMedCentral

41.

Sowerby L, Dewan AK, Granter S, Gandhi L, LeBoeuf NR (2017) Rituximab treatment of nivolumab-induced bullous pemphigoid. JAMA Dermatol 153(6):603–605. https://doi.org/10.1001/jamadermatol.2017.0091CrossRefPubMed

42.

Esfahani K, Elkrief A, Calabrese C, Lapointe R, Hudson M, Routy B, Miller WH Jr, Calabrese L (2020) Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol 17(8):504–515. https://doi.org/10.1038/s41571-020-0352-8CrossRefPubMed

43.

Monsour EP, Pothen J, Balaraman R (2019) A novel approach to the treatment of pembrolizumab-induced psoriasis exacerbation: a case report. Cureus 11(10):e5824. https://doi.org/10.7759/cureus.5824CrossRefPubMedPubMedCentral

44.

Williams HC, Wojnarowska F, Kirtschig G, Mason J, Godec TR, Schmidt E, Chalmers JR, Childs M, Walton S, Harman K, Chapman A, Whitham D, Nunn AJ, UK Dermatology Clinical Trials Network BLISTER Study Group (2017) Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet 389(10079):1630–1638. https://doi.org/10.1016/S0140-6736(17)30560-3CrossRefPubMedPubMedCentral

45.

Ito J, Fujimoto D, Nakamura A, Nagano T, Uehara K, Imai Y, Tomii K (2017) Aprepitant for refractory nivolumab-induced pruritus. Lung Cancer 109:58–61. https://doi.org/10.1016/j.lungcan.2017.04.020CrossRefPubMed

Title: Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors
Authors: Jennifer Choi
Ronald Anderson
Ada Blidner
Tim Cooksley
Michael Dougan
Ilya Glezerman
Pamela Ginex
Monica Girotra
Dipti Gupta
Douglas Johnson
Vickie R. Shannon
Maria Suarez-Almazor
Bernardo L. Rapoport
Mario E. Lacouture
Publication date: 01-12-2020
Publisher: Springer Berlin Heidelberg
Keywords: Bullous Pemphigoid
Stevens-Johnson Syndrome
Pruritus
Vitiligo
Checkpoint Inhibitors
Published in: Supportive Care in Cancer / Issue 12/2020
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-020-05706-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2020

Painful and non-painful chemotherapy-induced peripheral neuropathy and quality of life in colorectal cancer survivors: results from the population-based PROFILES registry

Immunotherapy-mediated dermatological adverse events: the urgent need for a common, clinically meaningful, management strategy

Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in gastrointestinal cancer patients with massive ascites treated with systemic chemotherapy

The clash between palliative care and COVID-19

Oral nutrition interventions in patients undergoing gastrointestinal surgery for cancer: A systematic literature review

Real-world experiences with acupuncture among breast cancer survivors: a cross-sectional survey study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer